Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 3/20 | 0.44 |
| ▸ | PARP10 | Q53GL7 | 5/20 | 0.43 |
| ▸ | PARP15 | Q460N3 | 4/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.40 |
| ▸ | F10 | P00742 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TLR4 | O00206 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27219399 | 0.85 | MCL1 (0.47) | MCL1MAPK1NPC1RAB9AGAA | |
| SCHEMBL15883736 | 0.85 | MCL1 (0.47) | MCL1MAPK1NPC1RAB9AGAA | |
| SCHEMBL27219385 | 0.83 | MAPK1 (0.44) | MCL1MAPK1NPC1RAB9AGAA | |
| SCHEMBL15883574 | 0.83 | MAPK1 (0.44) | MCL1MAPK1NPC1RAB9AGAA | |
| SCHEMBL27219489 | 0.81 | MCL1 (0.55) | MCL1MAPK1NPC1RAB9AALDH1A1 | |
| SCHEMBL15874857 | 0.80 | TP53 (0.50) | MAPK1CYP2C9NPC1RAB9AGAA | |
| SCHEMBL15874855 | 0.80 | TP53 (0.50) | MAPK1CYP2C9NPC1RAB9AGAA | |
| SCHEMBL6434415 | 0.79 | ESR2 (0.48) | MCL1NPC1RAB9ATLR4 | |
| SCHEMBL8381617 | 0.79 | DDB1 (0.50) | MCL1TLR4 | |
| Hydrogen Peroxide SCHEMBL14842506 | 0.77 | MCL1 (0.53) | MCL1GAAALDH1A1TLR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158340-A1 | PHOTOCATALYTIC ARYLATION OF CARBONYL COMPOUNDS AND METHODS FOR USING THE SAME | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2024-05-16 | — | — | US | disclosed |
| WO-2022235875-A1 | PHOTOCATALYTIC ARYLATION OF CARBONYL COMPOUNDS AND METHODS FOR USING THE SαAME | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2022-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158340-A1 | PHOTOCATALYTIC ARYLATION OF CARBONYL COMPOUNDS AND METHODS FOR USING THE SAME | AHR, CBR3, AADAC | F2 3382/4885PARP10 2395/4885PARP15 1068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.